< Back to latest news & events

Event

4th Microbiome: Recent Developments, Regulatory, Quality and Commercialization Summit

October 2020

Event date: 15th October 2020

HGF Partner Craig Thomson will be speaking at the 4th Microbiome: Recent Developments, Regulatory, Quality and Commercialization Summit on 15th October.

The Summit will shed light on current challenges, best practices, and inside views of the future of microbiome-based products in relation to the quality, safety, and efficiency.

The speakers will discuss key findings, critical insights, and recommendations for driving efficient strategies within the microbiome landscape.

HGF Partner Craig Thomson will be presenting on Thursday 15th October.

Microbiome and IP – How to Build a Commercially Relevant Patent Portfolio

For any Microbiome Innovator, there are many combinations of reasons to consider building an IP Portfolio: to protect a monopoly of sales for your product or service, to enhance valuation of your company for sale, to enhance your bargaining position with a collaborator or competitor, or to form part of the package designed to attract investors. No matter the reason, or combinations of reasons, a coherent IP strategy that recognises the specific timelines and commercial goals of your company is vital. Using the International IP systems to protect many of the innovations in the microbiome field has very specific challenges; adding another burden to the job of creating of an appropriate IP strategy. Indeed, an important part of such a strategy is the consideration of when not to protect by registered IP rights. Craig will provide a road-map of actions to be taken and considered when developing such strategies for a Microbiome innovator.

Attendees

Latest updates

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

IP Ingredients: The not so "Impossible" Burger

Meat alternatives are a hot topic with the increase in popularity of vegetarianism and veganism, highlighted by this month being “veganuary”.  However, at time when meat alternatives are coming under …

Read article

WTR 1000 2025

We are proud to announce that our European trade mark team has been recognised in the World Trade Mark Review 1000 2025. The firm is also proud to have 19 …

Read article

Court of Appeal Confirms No Second Medical Use SPCs in UK

Merck Serono SA  v  The Comptroller-General of Patents, Designs, and Trade Marks – Lewison LJ, Arnold LJ and Birss LJ – [2025] EWCA Civ 45 – 28 January 2025 The …

Read article

T 0295/22: Apremilast decision highlights hopes and challenges for broad second medical use claims

This case provides insight to the EPO’s interpretation of administration features in second medical use claims. Whilst the door appears to be open for broader second medical use claims, they …

Read article

T 1418/22: Acalabrutinib provides guidance on establishing inventiveness of polymorphs at the EPO

The EPO Board of Appeal’s decision in T 1418/22 gives useful guidance on the inventiveness of polymorph claims in Europe. Starting from a known amorphous form, a specific crystalline form …

Read article

HGF Celebrates Two Nominations at the Women and Diversity in Law Awards

We are proud to share that we have been nominated for two awards at The Women and Diversity in Law Awards which will take place on 18th March at Hilton …

Read article